Please type a plus sign (+) inside this box Π

PTO/SB/21 (6-99) Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
pollection of information unless it displays a valid OMB control number.

Under	ne Pape	rwork Reduction Act of	1995, no persons and	to respond to a	collection of	information unless it displays a valid OMB control num
	·			Application Num	ıber	10/697,599
TRANSMITTAL			Filing Date	iling Date October 29, 2003		
FORM			First Named Invo	entor	Austin L. GURNEY	
(to be used for all correspondence after initial filing)			Group/Art Unit		1644	
				Examiner Name		Unassigned
Total Number of I	Pages i	n This Submission		Attorney Docket	Number	39766-0125A
			ENCLOSUI	RES (check all that a	pply)	
Changes Affidavi Extension of Information	Responsal With Market M	farkings Showing faration(s) Request sure Statement ing 4 references on	Cor an April Drawing Drawing Licensin Petition and Accordance Petition Provisio Power of Change Termina Small En Request Remarks	g-related Papers Routing Slip (PTO/Slompanying Petition to Convert to a nal Application f Attorney, Revocation of Correspondence Additional Disclaimer natity Statement	n ddress	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Additional Enclosure(s) (please identify below): Copy of Supplementary Partial European Serach Report; copies of 4 cited references and a stamped return postcard.
	•	. ,	•	•		R AND REFERNCE 39766-0125A.
c:	1			LICANT, ATTORN	EY OR AC	GENT
Firm or Individual name	Ginger R. Dreger, Reg. No. 33,055 HELLER EHRMAN LLP					
Signature (10)						
Date	Janu	uary 24, 2006		Customer Numb	er: 25	213
			CEDTIE	ICATE OF MAIL IN	G	
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail" (EL 976 549 945 US) on the date indicated below and addressed to: Mail Stop: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450						
Typed or printed name Sandra Puljic						
Signature Andre		Puz	~	Date	January 25 ,2006	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:) Examiner: Unassigned
Austin L. GURNEY) Art Unit: 1644
Application Serial No. 10/697,599) Attorney's Docket No. 39766-0125A
Filed: October 29, 2003	Customer No. 25213
For: INHIBITION OF IL-17 PRODUCTION)) ·
)

EXPRESS MAIL LABEL NO. $\underline{\text{EL}}$ 976 549 945 $\underline{\text{US}}$

DATE MAILED: JANUARY 24, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §1.97-1.98.

In addition, enclosed is a copy of the Partial European Search Report received in the related matter for the above-identified application which discloses the references submitted herewith.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

M	This sta	atement q	ualifies	under 3/ C.F.R. §1.9/, subsection (b) because (check all that apply):		
			(1) than a c	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR		
			(2)	It is being filed within 3 months of entry of a national stage OR		
	\boxtimes		(3) merits	It is being filed before the mail date of the first Office Action on the		
			(4) of a req	OR It is being filed before the mailing of a first Office Action after the filing juest for continued examination under § 1.114.		
	filing d stage a action of	late of a n s set forth on the me	ational in §1.4 crits, bu	his statement is being filed after the latest of: (1) three months beyond the application; (2) three months beyond the date of entry of the national 491 in an international application; or (3) the mailing date of a first Office t before the mailing date of the earlier of a final office action under §1.113 and under §1.311, then:		
	\boxtimes	a certific	cation a	s specified in §1.97(e) is provided below; or		
				as set forth in §1.17(p) is authorized below, enclosed, or included with other papers filed together with this statement.		
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:					
	A.	a certific	cation a	s specified in §1.97(e) is completed below; and		
	B. ·	_		37 C.F.R. §1.97(d) requesting consideration of this statement is with; and		
	C.		•	0 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with other papers filed together with this statement.		
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39766-0125A).					
				Respectfully submitted,		
Dated:	January	y 24, 200e	6	By Ginger R. Dreger (Reg. No. 33,055)		
	ER EH	RMAN, I d Road	LLP	·		

-2-

Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

CERTIFICATION

(Attachment to Information Disclosure Statement)

	37 C.F.R.§1.97(e)(1). APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement; or
	37 C.F.R.§1.97(e)(2). APPLICANT'S UNDERSIGNED ATTORNEY HEREBY CERTIFIES THAT no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.
	Respectfully submitted,
Dated:	January 24, 2006 By: Ginger R. Dreger (Reg. No. 33,055)

Application Serial No. Form PTO-1449 Attorney's Docket No. 39766-0125A 10/697.599 Applicant(s) MATION DISCLOSURE STATEMENT Austin L. GURNEY Filing Date: **Group Art Unit:** October 29, 2003 (use several sheets if necessary) 1644 U.S. PATENT DOCUMENTS 1 **Subclass** Filing Date Examiner Ref. Date Document No. Name Class (if appropriate) Initials No. FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Name Class **Subclass** Translation Initials No. YES NO OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Ref. Title Examiner Initials No. 1. Aarvak, T., et al., "Change in the Th1/Th2 Phenotype of Memory T-Cell Clones from Rheumatoid Arthritis Synovium", Scandinavian Journal of Immunology, Vol. 50, No. 1-9, 1999. (XP-002352889) 2. Brok, Herbert P. M, et al., "Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody, The Journal of Immunology, Vol. 169, pp 6554-6563, 2002. (XP-002971968) 3. Maeyama, Takashige, et al., "Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12", American Journal of Physiology, Lung Cellular and Molecular Physiology, Vol. 280, No. 6, pp L1128-L1137, June 2001. (XP-002352888) Tripp, Catherine S., et al., "Neutralization of IL-12 Decreases Resistance to Listeria in SCID and C.B-17 Mice Reversal 4. by IFN-Gamma", Journal of Immunology, Vol. 152, pp 1883-1887, 1994. (XP-002924062)

EXAMINER:	DATE CONSIDERED:	<i>x</i>
		•

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2176931 v2